It was confirmed on the 24th that the "largest-ever order since its founding" that Samsung Biologics released last year was an internal transaction at the time with its subsidiary Samsung Bioepis. In the industry, there are criticisms of "Director promotion."
Samsung Biologics announced on Oct. 22 last year that it had signed a contract manufacturing (CMO) deal worth 1.7 trillion won. Without disclosing the client or product name, it only said it was "a pharmaceutical company based in Asia," adding that it planned to open a sales office in Tokyo, Japan, to strengthen cooperation. Because of this, the securities community analyzed that it may have won volumes from major Japanese pharmaceutical companies such as Takeda Pharmaceutical and Daiichi Sankyo.
Regarding this, a Samsung Biologics official said, "To protect client information, we do not disclose client names, regardless of whether they are affiliates, without the client's consent."
The size of internal transactions between Samsung Biologics and Samsung Bioepis has surged over the past three years. It grew 78.6% from 148.1 billion won in 2022 to 264.5 billion won in 2023, and increased 84.3% year over year to 487.6 billion won in 2024.